AIM ImmunoTech

AIM ImmunoTech Employees

The The number of employees of AIM ImmunoTech (AIM) as of Nov 18, 2026 is 31. In the previous year, The number of employees was 31.00 — a change of 0.00% (lower).

Employees

31

YoY

0.00%

Last updated:

In 2025, AIM ImmunoTech employed 31 people, a 0.00% change from the 31.00 number of employees in the previous year.

The AIM ImmunoTech Employees history

  • 3 Years

  • 10 Years

  • 25 Years

  • Max

Employees
Date
Employees
Jan 1, 2018
31.00 USD
Jan 1, 2019
31.00 USD
Jan 1, 2020
31.00 USD
Jan 1, 2021
31.00 USD
Jan 1, 2022
31.00 USD
Jan 1, 2023
31.00 USD
Jan 1, 2024
31.00 USD
Jan 1, 2025
31.00 USD
The AIM ImmunoTech Employees history
YEAREmployeesYoY
310.00%
310.00%
310.00%
310.00%
310.00%
310.00%
310.00%
310.00%
310.00%
310.00%
310.00%
31—

Access this data via the Eulerpool API

100,000 free requests/mo · no credit card

AIM ImmunoTech Stock analysis

What does AIM ImmunoTech do? AIM ImmunoTech, Inc. generates revenue primarily through the sales and marketing of Alferon N Injection, an approved treatment for refractory or recurring external genital warts in patients over 18. The company also develops Ampligen, a drug in clinical development for Chronic Fatigue Syndrome, and Alferon LDO, a low-dose oral liquid formulation of natural alpha interferon. Its primary customer segments include patients with viral and immune-based chronic disorders requiring specialized therapies. The firm's R&D segment focuses on Ampligen and other drugs under development, while its commercial segment handles Alferon product sales. Alferon N Injection is marketed for intralesional treatment of genital warts, targeting healthcare providers who prescribe it to adult patients. Ampligen is positioned for clinical trials in Chronic Fatigue Syndrome, with potential future commercialization. Alferon LDO represents a novel oral delivery method for natural interferon, targeting patients seeking non-invasive treatment options. The company's revenue streams are derived from both current product sales and future potential drug development milestones. The firm's business model centers on leveraging natural immune system enhancing technologies to address unmet medical needs in viral and immune-based disorders. Its products are developed through clinical trials and regulatory approvals, with Alferon N Injection already approved for specific indications. The company's focus on R&D and commercialization of these therapies defines its market position within the biopharmaceutical sector. AIM ImmunoTech is one of the most popular companies on Eulerpool.

Employees Details

Examining AIM ImmunoTech's Employee Base

AIM ImmunoTech's employees are a pivotal aspect of its operations, driving innovation, productivity, and growth. The size and composition of the workforce offer insights into the company's scale, diversity, and investment in human capital. Analyzing employee trends and data is essential for understanding AIM ImmunoTech's operational capacity and future potential.

Year-to-Year Comparison

Assessing AIM ImmunoTech's employee numbers year-over-year helps in identifying growth patterns, expansions, or contractions. An increasing employee count can indicate scaling operations and investment in talent, while a decrease may signal efficiency improvements, automation, or business challenges.

Impact on Investments

AIM ImmunoTech's employee data impacts investment decisions by shedding light on the company’s operational efficiency, innovation capability, and sustainability. Investors assess workforce data to gauge the firm's potential to execute strategies, innovate, and adapt to market changes effectively.

Interpreting Employee Trends

Fluctuations in AIM ImmunoTech’s employee numbers indicate changes in business strategy, operational demands, and market dynamics. Investors and analysts scrutinize these trends to evaluate the company’s strategic positioning, adaptability, and potential for sustainable growth.

Frequently Asked Questions about AIM ImmunoTech stock

The number of employees of AIM ImmunoTech is 31 in 2025.

The number of employees of AIM ImmunoTech changed from 31.00 to 31, representing a 0.00% change. The value is lower than the previous year.

On Eulerpool you can find the complete historical development of The number of employees AIM ImmunoTech since 2006 – with annual values, charts, and detailed analysis.

The number of employees describes the number of people directly employed by the company.

The number of employees's is a key factor for investors. Changes in this metric can signal improving or deteriorating fundamentals, directly impacting the stock price. On Eulerpool, you can track The number of employees's AIM ImmunoTech historically and in real time.

Access this data via the Eulerpool API

100,000 free requests/mo · no credit card

Workforce — AIM ImmunoTech

All Key Metrics — AIM ImmunoTech